|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis显示文摘 | Ana-Carolina Cardoso Rami Moucari Claudio Figueiredo-Mendes Marie-Pierre Ripault Nathalie Giuily Corinne Castelnau Nathalie Boyer Tarik Asselah Michelle Martinot-Peignoux Sarah Maylin Roberto J. Carvalho-Filho Dominique Valla Pierre Bedossa Patrick Marcel | 2010 | Journal of Hepatology2010，，5： | 3 |
| 2 | Usefulness of longitudinal evaluation of CYFRA21-1 variations in advanced lung cancer monitoring显示文摘 | Hamzaoui A Thomas P Castelnau O | 1997 | Lung Cancer1997，16，： | 1 |
| 3 | Thermal creep of Zr- Nh1 %-O alloys: experimental analysis and micromechanical modeling 显示文摘 | Brenner R Bechade J Castelnau O | 2002 | Journal of Nuclear Materials2002，305，： | 1 |
| 4 | Impact of ribavirin dose on retreatment of chronic hepatitis C patients显示文摘AIM: To study the efficacy and factors associated with a sustained virological response (SVR) in chronic hepatitis C (CHC) relapsing patients. METHODS: Out of 1228 CHC patients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV), 165 (13%) had a relapse. Among these, 62 patients were retreated with PEG-IFN-2a or-2b and RBV. Clinical, biological, virological and histological data were collected. Initial doses and treatment modifications were recorded. The efficacy of retreatment and predictive factors for SVR were analyzed. RESULTS: An SVR was achieved in 42% of patients. SVR was higher in young (< 50 years) (61%) than old patients (27%) (P = 0.007), and in genotype 2 or 3 (57%) than in genotype 1 or 4 (28%) patients (P = 0.023). Prolonging therapy for at least 24 wk more than the previous course was associated with higher SVR rates (53% vs 28%, P = 0.04). Also, a better SVR rate was observed with RBV dose/body weight > 15.2 mg/kg per day (70% vs 35%, P = 0.04). In logistic regression, predictors of a response were age (P = 0.018), genotype (P = 0.048) and initial RBV dose/body weight (P = 0.022). None of the patients without a complete early virological response achieved an SVR (negative predictive value = 100%). CONCLUSION: Retreatment with PEG-IFN/RBV is effective in genotype 2 or 3 relapsers, especially in young patients. A high dose of RBV seems to be important for the retreatment response. | Christiane Stern Michelle Martinot-Peignoux Marie Pierre Ripault Nathalie Boyer Corinne Castelnau Dominique Valla Patrick Marcellin | 2012 | World Journal of Gastroenterology2012，18，23： | 1 |
| 5 | The Current Status of Antiviral Therapy of Chronic Hepatitis B显示文摘 | ASSELAH T RIPAULT MP CASTELNAU C | 2005 | J Clin Virol(S1386-6532)2005，34，1： | 1 |
| 6 | The current status of antiviral therapy of chronic hepatitis B显示文摘 | Tarik Asselah Marie-Pierre Ripault Corinne Castelnau | 2005 | Journal of Clinical Virology2005，11，： | 1 |
| 7 | The current status of antiviral therapy of chronic hepatitis B显示文摘 | Asselah T Ripault M P Castelnau C | 2005 | J Clin Virol2005，34，1： | 1 |
| 8 | Pallidal stimulation improves pantothenate kinase-associated neurodegeneration显示文摘 | Castelnau P Cif L Valente EM | 2005 | Ann Neurol2005，57，5： | 1 |
| 9 | Usefulness of longitudinal evaluation of CYFRA21 - 1 variations in advanced lung cancer monitoring显示文摘 | Hamzaoui A Thomas P Castelnau O | 1997 | Lung cancer1997，1，： | 1 |
| 10 | Thin Solid Films 显示文摘 | Castelnau O Geandier G Renault P O | 2007 | 516(2-4):3202007，516，24： | 1 |
| 11 | Thermal creep of Zr-Nb1%-O alloys:Experimental analysis and micromechanical modeling显示文摘 | BECHADE J L CASTELNAU O | 2002 | Journal of Nuclear Materials2002，305，： | 1 |
| 12 | Treatment of chronic hepatitis B显示文摘 | ASSELAH T CASTELNAU C MARCELLIN P | 2006 | Presse Med2006，35，22： | 1 |
| 13 | Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients显示文摘 | Rami Moucari Vincent Mackiewicz Olivier Lada Marie‐Pierre Ripault Corinne Castelnau Michelle Martinot‐Peignoux Agnes Dauvergne Tarik Asselah Nathalie Boyer Pierre Bedossa Dominique Valla Michel Vidaud Marie‐Hélène Nicolas‐Chanoine Patrick Marcellin | 2009 | Hepatology2009，，4： | 1 |
| 14 | Usefulness of longitudinal e- valuation of CYFRA21-1 varaiations in advanced lung cancer monitoring 显示文摘 | Hammzaoui A Thomas P Castelnau O | 1997 | Lung cancer1997，16，： | 1 |
| 15 | Usefulness of longitudinal evaluation of CYFRA21-1 variations in advanced lung cancer monitoring显示文摘 | Hamzaoui A Thomas P Castelnau O | 1997 | Lung Cancer1997，16，： | 1 |
| 16 | Texture evolution and associated nucleation and growth mechanisms during annealing of a Zr Alloy 显示文摘 | ZHU K Y BACROIX B CHAUYEAU T CHAUBET D CASTELNAU O | 2009 | Metallurgical and Materials Transactions A2009，40，： | 1 |
| 17 | Natural history of hepatitis B显示文摘 | Marcellin P Castelnau C Martinot-Peignoux M | 2005 | Minerva Gastroenterol Dietol2005，51，1： | 1 |
| 18 | Use of methylphenidate in adults with attention deficitdisorder-with hyperactivity显示文摘 | Gauillard J Castelnau C Vacheron-Trystram | 1997 | Encephale1997，23，4： | 1 |
| 19 | A study of EEGcoherence in DCD children during motor synchronizationtask显示文摘 | De Castelnau P Albaret JM Chaix Y etaL | 2008 | Human Movement Science2008，27，： | 1 |
| 20 | The current status of antiviral therapy of chronic hepatitis B 显示文摘 | Asselah T Ripault M P Castelnau C | 2005 | J Clin Virol2005，34，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员